CorMedix (CRMD) Other Non-Current Liabilities (2013 - 2026)

CorMedix (CRMD) posted Other Non-Current Liabilities of $163403.0 for Q4 2021, down 91.31% sequentially from $1.9 million in Q2 2017.

CorMedix (CRMD) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends

CorMedix has reported Other Non-Current Liabilities for 3 years, with the latest figure at $163403.0 in Q4 2021.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $163403.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $163403.0 (changed N/A YoY) and the FY2021 annual result came in at $163403.0, changed N/A from the prior year.
Other Non-Current Liabilities eased to $163403.0 in Q4 2021 per CRMD's latest filing, from $1.9 million in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $1.9 million in Q2 2017 and troughed at $163403.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn

Download Data